Baxter gets FDA nod for FEIBA as a prophylactic

|About: Baxter International Inc (BAX)|By:, SA News Editor

Baxter (BAX -0.5%) gets another indication for the hemophilia treatment FEIBA.

The FDA has approved the drug for the prophylactic treatment of patients with hemophilia A or B who have developed inhibitors.

"This additional indication ... is aimed at reducing the number of bleeds among this patient population," the company's president of BioScience says. (PR)